Incyte (INCY) revenue breakdown
By product, JAKAFI is the largest at 60% of fiscal 2025 revenue; OPZELURA grew fastest, 247% a year over 4 years.
By region, United States is the largest at 93% of fiscal 2025 revenue; Europe grew fastest, 59% a year over 3 years.
Revenue by product
Fiscal years, as Incyte reports them in its 10-K filings; fiscal 2025 total $5.1B.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| JAKAFI | $1.1B | $1.4B | $1.7B | $1.9B | $2.1B | $2.4B | $2.6B | $2.8B | $3.1B | 60% |
| OPZELURA | — | — | — | — | $5M | $129M | $338M | $508M | $678M | 13% |
| JAKAVI Royalty Revenues | $152M | $195M | $226M | $278M | $338M | $332M | $368M | $419M | $458M | 9% |
| NIKTIMVO | — | — | — | — | — | — | — | — | $152M | 3% |
| Milestone and contract revenues | $175M | $180M | $78M | $205M | $95M | $165M | $7M | $43M | $150M | 3% |
| OLUMIANT Royalty Revenues | $9M | $40M | $80M | $111M | $221M | $135M | $136M | $136M | $145M | 3% |
| MINJUVI/MONJUVI | — | — | — | — | $5M | $20M | $37M | $119M | $145M | 3% |
| ICLUSIG | — | — | — | $105M | $109M | $106M | $112M | $114M | $134M | 3% |
| PEMAZYRE | — | — | $90M | $26M | $69M | $83M | $84M | $82M | $87M | 2% |
| ZYNYZ | — | — | — | — | — | — | $1M | $3M | $66M | 1% |
| TABRECTA Royalty Revenues | — | — | — | $4M | $10M | $15M | $18M | $23M | $27M | 1% |
| Other product royalty revenues | — | — | — | — | — | $1M | $2M | $2M | $8M | 0% |
| ICLUSIG | $67M | $80M | — | — | — | — | — | — | — | — |
| Other revenues | — | $203,000 | — | — | — | — | — | — | — | — |
| Other revenues | $113,000 | — | — | — | — | — | — | — | — | — |
Revenue by region
Fiscal years, as Incyte reports them in its 10-K filings; fiscal 2025 total $5.1B.
| Regions | 2018 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|
| United States | $1.8B | $3.5B | $4.0B | $4.8B | 93% |
| Europe | $80M | $176M | $260M | $324M | 6% |
| Other countries | — | $5M | $6M | $18M | 0% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for INCY.
Open INCY in InvestinglyQuestions
Where does Incyte make its money?
In fiscal 2025, by product: JAKAFI $3.1B, OPZELURA $678M, JAKAVI Royalty Revenues $458M, NIKTIMVO $152M, Milestone and contract revenues $150M.
From Incyte's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.